Scientists seek to improve flu vaccine for the very young

February 11, 2016
Scientists seek to improve flu vaccine for the very young

Scientists at the University of Rochester School of Medicine and Dentistry have discovered a way to make a nasal spray flu vaccine safer for those who are at greatest risk of catching the flu, particularly infants under the age of 2. The work is early and a long way from being applied in people, but offers promise for a vaccine that could better protect the most vulnerable.

The currently available , FluMist, is one of several types of flu vaccines offered every year, but it is only approved for use in people 2 through 49 years old. Infants, asthmatics, and older adults are not eligible for the vaccine, which is made from live virus that is dampened down so that it doesn't cause the flu. Because the virus is live, it activates multiple components of the immune system and creates a more robust than the traditional shot version of the vaccine, which includes inactivated or killed flu virus.

Working with a vaccine similar to FluMist that is used in mice, Andrew Cox, a graduate student in the laboratory of Stephen Dewhurst, Ph.D., used molecular genetics to alter the vaccine virus so that it replicates only in the nose and not in the lungs. This is important because the main reason FluMist was not approved for use in children under the age of 2 is that it was associated with wheezing in infants in clinical trials.

A flu vaccine is delivered via a spray into each nostril and moves from the nose through the respiratory tract to the lungs. Cox says that if a vaccine virus enters the lungs it can create inflammation in response to the virus. This presents a problem in very young children with narrow airways that are easily constricted. If the vaccine virus stays only in the nose, it eliminates the potential for wheezing, making it a safer option for infants, as well as individuals with asthma.

"No one has tried to tweak a vaccine virus like this before," said Cox, lead author of the study, which appears today in the Journal of Virology. "If we can make the nasal spray safer for very young children, it should provide better protection and remove a shot, which makes children and parents happy."

"FluMist is very safe in the populations that it is licensed for and creates a good immune response in kids ages 2 to 5, who are very susceptible to flu," added John J. Treanor, M.D., chief of the Infectious Diseases Division at UR Medicine's Strong Memorial Hospital. "It would be a major accomplishment if we were able to develop a live vaccine like FluMist for children ages 6 to 24 months."

Treanor and Cox say that many pediatricians stock the regular flu shot and not FluMist because the shot can be used for all ages. Cox says that in most cases, if a parent wants FluMist, he or she has to ask for it, like he did for his 3 year old son last November.

"Not many doses of FluMist are given out, and that is a missed opportunity," added Cox, who is participating in a rigorous M.D./Ph.D. program at the School of Medicine and Dentistry plans to specialize in pediatric infectious diseases.

In 2013, Cox applied for and won a Technology Development Fund (TDF) award from UR Ventures, a branch of the University that helps transfer ideas and technologies from the Medical Center and the River Campus to the private sector for commercialization. Cox is one of just two graduate students who have received funding since the TDF award program was launched in 2010. Cox used the award to conduct this research and a patent is pending on the new vaccine technology.

"This puts us closer to having a safe and effective that can be used in people at greatest risk," concluded Dewhurst, vice dean for research and chair of the Department of Microbiology and Immunology. He and Cox plan to continue this work in partnership with scientists from the Icahn School of Medicine at Mount Sinai.

Explore further: FDA approves first 4-in-1 flu vaccine

Related Stories

FDA approves first 4-in-1 flu vaccine

February 29, 2012

Federal health officials have approved the first vaccine that protects against four strains of the common flu, offering one additional layer of protection against the influenza virus that affects millions each year.

Do-it-yourself flu vaccine? Study shows it works

October 8, 2014

A study suggests that do-it-yourself flu vaccine might be possible. Researchers found that military folks who squirted a nasal vaccine up their noses were as well-protected as others who got it from health workers.

Developing a better flu vaccine

August 10, 2015

Johns Hopkins Bloomberg School of Public Health researchers say they have developed a method that could make a nasal spray flu vaccine effective for those under two and over 49 - two groups for which the vaccine is not approved.

Recommended for you

The 'love hormone' may quiet tinnitus

September 23, 2016

(HealthDay)—People suffering from chronic ringing in the ears—called tinnitus—may find some relief by spraying the hormone oxytocin in their nose, a small initial study by Brazilian researchers suggests.

Bile acid uptake inhibitor prevents NASH / fatty liver in mice

September 21, 2016

Drugs that interfere with bile acid recycling can prevent several aspects of NASH (nonalcoholic steatohepatitis) in mice fed a high-fat diet, scientists from Emory University School of Medicine and Children's Healthcare of ...

New therapeutic target for Crohn's disease

September 20, 2016

Research from the Sanford Burnham Prebys Medical Discovery Institute (SBP) identifies a promising new target for future drugs to treat inflammatory bowel disease (IBD). The study, published today in Cell Reports, also indicates ...

Mosquitoes, Zika and biotech regulation

September 19, 2016

In a new Policy Forum article in Science, NC State professor Jennifer Kuzma argues that federal authorities are missing an opportunity to revise outdated regulatory processes not fit for modern innovations in biotechnology, ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.